Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) have earned a consensus rating of “Hold” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $13.80.

Several research firms have recently weighed in on ABUS. JMP Securities reiterated an “outperform” rating and issued a $13.00 price target (up previously from $12.00) on shares of Arbutus Biopharma in a report on Wednesday, October 4th. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma in a report on Tuesday. Zacks Investment Research cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Finally, ValuEngine cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th.

A number of institutional investors and hedge funds have recently made changes to their positions in ABUS. Point72 Asset Management L.P. acquired a new position in Arbutus Biopharma during the third quarter worth $1,393,000. RTW Investments LP boosted its holdings in Arbutus Biopharma by 1.1% during the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock worth $32,651,000 after purchasing an additional 56,457 shares during the last quarter. OxFORD Asset Management LLP boosted its holdings in Arbutus Biopharma by 49.2% during the third quarter. OxFORD Asset Management LLP now owns 124,273 shares of the biopharmaceutical company’s stock worth $778,000 after purchasing an additional 40,963 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Arbutus Biopharma by 2.7% during the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 2,035 shares during the last quarter. Institutional investors and hedge funds own 59.97% of the company’s stock.

Arbutus Biopharma (ABUS) remained flat at $$5.20 during trading on Friday. 99,783 shares of the company traded hands, compared to its average volume of 159,511. The company has a market cap of $286.27, a price-to-earnings ratio of -1.05 and a beta of 1.08. Arbutus Biopharma has a one year low of $2.35 and a one year high of $8.25. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.21. equities research analysts predict that Arbutus Biopharma will post -1.29 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Arbutus Biopharma Corp (ABUS) Given Consensus Rating of “Hold” by Brokerages” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/20/arbutus-biopharma-corp-abus-given-consensus-rating-of-hold-by-brokerages.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.